Exploiting innate immunity for cancer immunotherapy
M Yi, T Li, M Niu, Q Mei, B Zhao, Q Chu, Z Dai, K Wu - Molecular cancer, 2023 - Springer
Immunotherapies have revolutionized the treatment paradigms of various types of cancers.
However, most of these immunomodulatory strategies focus on harnessing adaptive …
However, most of these immunomodulatory strategies focus on harnessing adaptive …
Targeting cytokine and chemokine signaling pathways for cancer therapy
Cytokines are critical in regulating immune responses and cellular behavior, playing dual
roles in both normal physiology and the pathology of diseases such as cancer. These …
roles in both normal physiology and the pathology of diseases such as cancer. These …
Tumor‐tailored ionizable lipid nanoparticles facilitate IL‐12 circular RNA delivery for enhanced lung cancer immunotherapy
The advancement of message RNA (mRNA)‐based immunotherapies for cancer is highly
dependent on the effective delivery of RNA (Ribonucleic) payloads using ionizable lipid …
dependent on the effective delivery of RNA (Ribonucleic) payloads using ionizable lipid …
Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities
B Wang, J Pei, S Xu, J Liu, J Yu - Frontiers in immunology, 2023 - frontiersin.org
Since the successful application of messenger RNA (mRNA) vaccines in preventing COVID-
19, researchers have been striving to develop mRNA vaccines for clinical use, including …
19, researchers have been striving to develop mRNA vaccines for clinical use, including …
mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy
I Olivera, E Bolaños, J Gonzalez-Gomariz… - Cell Reports …, 2023 - cell.com
Summary Interleukin-12 (IL-12) gene transfer enhances the therapeutic potency of adoptive
T cell therapies. We previously reported that transient engineering of tumor-specific CD8 T …
T cell therapies. We previously reported that transient engineering of tumor-specific CD8 T …
Lipid-based nanosystems: the next generation of cancer immune therapy
Immunotherapy has become an important part of the oncotherapy arsenal. Its applicability in
various cancer types is impressive, as well as its use of endogenous mechanisms to achieve …
various cancer types is impressive, as well as its use of endogenous mechanisms to achieve …
Synthetic macromolecular switches for precision control of therapeutic cell functions
Cells rely on complex molecular networks to perceive and process external and internal
signals into tailored responses. These cellular abilities can be augmented and modified by …
signals into tailored responses. These cellular abilities can be augmented and modified by …
Cisplatin-induced pyroptosis enhances the efficacy of PD-L1 inhibitor in small-cell lung cancer via GSDME/IL12/CD4Tem axis
W Xuzhang, T Lu, W **, Y Yu, Z Li… - International …, 2024 - pmc.ncbi.nlm.nih.gov
The combination therapy of platinum-based chemotherapy and PD-L1 inhibitors but not the
single anti-PD-L1 therapy has significantly improved the prognosis of patients with small-cell …
single anti-PD-L1 therapy has significantly improved the prognosis of patients with small-cell …
In situ cocktail nanovaccine for cancer immunotherapy
M Liu, D **e, D Hu, R Zhang, Y Wang, L Tang… - Advanced …, 2023 - Wiley Online Library
In situ vaccination is a desirable strategy for cancer immunotherapy due to its convenience
and capacity to target tumor antigens. Here, an in situ nanovaccine based on a cationic …
and capacity to target tumor antigens. Here, an in situ nanovaccine based on a cationic …
Emerging mRNA technology for liver disease therapy
J Wang, Y Fang, Z Luo, J Wang, Y Zhao - ACS nano, 2024 - ACS Publications
Liver diseases have consistently posed substantial challenges to global health. It is crucial
to find innovative methods to effectively prevent and treat these diseases. In recent times …
to find innovative methods to effectively prevent and treat these diseases. In recent times …